The Food and Drug Administration (FDA) warns the public from purchasing and using the following non-compliant cosmetic products imported and distributed by the Market Authorization Holder (MAH), Healthy Innovation Distribution Inc.:
- FRESH SKINLAB COLLAGEN SPF 50 FACE AND BODY MIST
- FRESH SKINLAB ALOE VERA FACE MIST
- SUNGLOW BY FRESH SUN MIST SPF 50
- FRESH SKINLAB 98% TOMATO GLASS SKIN SPF 50 FACE & BODY MIST
According to Republic Act 3720, a cosmetic shall be deemed to be misbranded if its labeling is false or misleading in any particular. Furthermore, IRR of Republic Act 9711 defines “misbranding” as giving unsubstantiated claims, misinformation or misleading information on the label or other information materials.
The aforementioned cosmetic products were found and tested to be non-compliant with the existing standards based on its failure to meet its Sun Protection Factor (SPF) 50 claim. Also, the MAH, Healthy Innovation Distribution Inc., has made misrepresentation and false entries in the applications for product notification based on the Centers’ post evaluation activities rendering the products as being misbranded.
In light of the foregoing, the public is advised not to purchase the aforementioned misbranded products. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (www.fda.gov.ph.) has a Search feature which may be used by typing in the name of the product before purchasing.
All concerned establishments are warned not to distribute misbranded cosmetic products.
All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.
To report any sale, distribution, complaint and/or adverse event on the use of the violative cosmetic product, the online reporting facility, eReport can be accessed at [email protected], or call us at the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 8857-1900 loc. 8113 or 8107.
Dissemination of this advisory to all concerned is hereby requested.
Attachment:-> FDA-Advisory-No.2020-1626